Anna and her GMP Development Unit at Fraunhofer IZI are specialized in translating immature laboratory processes into GMP-compliant manufacturing workflows for immune-cell–based therapies. Her core competencies include GMP process optimization, upscaling, automation and quality control development for cell and gene therapies. She maintains a strong focus on the regulatory landscape for advanced therapy medicinal products (ATMPs) and immunotherapies, and leads process development for innovative cancer immunotherapy initiatives and new products. Her current research focuses on allogeneic T cell-based products, engineered NK cells and CAR macrophages for adoptive therapy.